The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study
Abstract
Purpose:
We assessed whether dutasteride enhances the usefulness of total prostate specific antigen for diagnosing clinically significant prostate cancer.
Materials and Methods:
The 4-year REDUCE study evaluated the efficacy and safety of 0.5 mg dutasteride daily for prostate cancer risk reduction in men with a prostate specific antigen of 2.5 to 10.0 ng/ml and a negative prostate biopsy. Specificity, sensitivity, and positive and negative predictive values of prostate specific antigen for the diagnosis of prostate cancer were assessed.
Results:
Final prostate specific antigen before biopsy and change from month 6 to final prostate specific antigen performed better for the diagnosis of Gleason score 7–10 tumors in men who received dutasteride vs placebo as assessed by the area under the ROC curves (0.700 vs 0.650, p = 0.0491; and 0.699 vs 0.593, p = 0.0001, respectively). Increases in prostate specific antigen were associated with a higher likelihood of biopsy detectable, Gleason score 7–10 and clinically significant (modified Epstein criteria) prostate cancer. Percentage decreases in prostate specific antigen from baseline to month 6 in the dutasteride arm did not predict prostate cancer overall or Gleason score 7–10 cancer.
Conclusions:
In men with a previously negative prostate biopsy, prostate specific antigen performed better during the 4-year study as a marker of prostate cancer in men who received dutasteride vs placebo. The degree of prostate specific antigen increase after 6 months was a better indicator of clinically significant cancer in the dutasteride arm than in the placebo arm. Conversely, the initial decrease in prostate specific antigen in men taking dutasteride did not predict the likelihood of prostate cancer.
References
- 1 : PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?. Eur Urol2008; 54: 262. Google Scholar
- 2 : Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol2007; 25: 3. Google Scholar
- 3 Andriole GL, Bostwick DG, Brawley OW et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192. Google Scholar
- 4 : Three considerations before advising 5-alpha-reductase inhibitors for chemoprevention. J Clin Oncol2009; 27: e22. Google Scholar
- 5 : Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol2004; 172: 1314. Link, Google Scholar
- 6 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Crossref, Medline, Google Scholar
- 7 : Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride. J Urol2006; 175: 1657. Link, Google Scholar
- 8 : Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial: Proscar Long-term Efficacy and Safety Study . Urology1998; 52: 195. Google Scholar
- 9 : Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol2001; 166: 1679. Link, Google Scholar
- 10 : Serial biopsy results in prostate cancer screening study. J Urol2002; 167: 2435. Link, Google Scholar
- 11 : Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol2007; 25: 3076. Google Scholar
- 12 : Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst2006; 98: 1128. Google Scholar
- 13 : Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst2007; 99: 1375. Google Scholar
